CSL, a global bioengineering company, said the company would integrate its subsidiaries into one corporate family under the global CSL brand.
"As a goal-oriented organization, CSL has demonstrated excellent leadership in biotechnology for more than a century. It is the right time to develop sustainable growth strategies further and integrate all subsidiaries into the CSL brand,” CSL CEO Paul Perreault said last Thursday.
"With one purpose, one strategy, one value, and now one integrated brand, our identity will be established," he added.
Under the brand integration, the company will rename Sequirus, an influenza vaccine company, CSL Seqirus, and recently acquired Vifor Pharma, CSL Vifor. Both subsidiaries will proceed with the formal process of changing their names. CSL Behring, a company specializing in rare and severe diseases, and CSL Plasma, a plasma collection company, maintain their current mission.
The company expects that the brand integration campaign, including the name change, will help establish its new global identity.
"All CSL's subsidiaries will provide innovative products and services to patients and people in more than 100 countries as they do today," Perreault said. “All of our 30,000 employees will keep their commitments to showcasing innovation in everything, including its passion, products, and performance for the sake of patients and human health.”